Presentation (CTI)

OBJECTIVES: Anakinra is indicated and reimbursed for the treatment of cryopyrin-associated periodic syndrome (CAPS), familial Mediterranean fever (FMF) and Still’s disease which includes both systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD) in Turkiye. Other molecules reimbursed for these diseases include canakinumab (for CAPS, FMF and SJIA) and tocilizumab (for SJIA). The objective of this study is to analyze the budget impact of switching anakinra’s reimbursement from the Imported Drugs Scheme (4/C) to full reimbursement (4/A) by the Turkish Social Security Institution (SGK) and to demonstrate the potential budget savings.
METHODS: We followed the budget impact analysis methodology used by the SGK. According to SGK reimbursement guidelines, a budget impact analysis for three years is necessary to demonstrate the financial impact of reimbursing a new molecule. The analysis included potential market share with and without anakinra along with the public prices of all products reimbursed for relevant indications. Anakinra was initially reimbursed under the Imported Drugs List scheme (Attachment 4C) until December 2024 in Türkiye. Therefore, comparisons were made between the availability of the drug under this scheme and after full reimbursement (Attachment 4A).
RESULTS: The total market value for anakinra (under 4C), canakinumab and tocilizumab was calculated as 3,597,673,589 TRY for 2025, 3,890,413.803 TRY for 2026 and 4,245,539,587 TRY for 2027. After the full reimbursement of anakinra, the total market value was 2,633,982,678 TRY, 2,773,976,914 TRY and 2,992,588,349 TRY for 2025, 2026 and 2027 respectively.
CONCLUSIONS: Anakinra is a budget saving option for the SGK in treating CAPS, FMF and Still’s disease in Turkiye. The SGK is expected to save 963,690,911 TRY in 2025, 1,116,436,889 TRY in 2026 and 1,252,951,238 TRY in 2027. The total savings over three years amount to 3,333,079,038 TRY.